Fexofenadine hydrochloride

Fexofenadine hydrochloride (CAS 138452-21-8) is a selective peripheral H1-receptor antagonist used as the active pharmaceutical ingredient in non-sedating antihistamine formulations. It is marketed under trade names including Allegra, Telfast, and Alernex, and is commonly abbreviated as Fexo or Fexofen in pharmaceutical procurement contexts.

The compound is primarily used in the manufacture of oral antihistamine drug products for the treatment of allergic rhinitis and chronic idiopathic urticaria. It works by selectively blocking peripheral histamine H1 receptors without crossing the blood-brain barrier, which eliminates the central nervous system sedation associated with earlier antihistamines. It is also used as a reference standard and analytical comparator in bioequivalence studies.

Fexofenadine hydrochloride is available in pharmaceutical-grade form compliant with Ph.Eur. and USP monograph specifications. Suppliers typically offer the material in controlled packaging under defined storage conditions to maintain stability. REACH registration status should be confirmed with the supplier prior to import into the European Economic Area.